Evidence map›Paper›PMID 41001470›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts.

Daniel Bello, Sophia H Blyth, Rachel A Rabin, Jean Addington, Carrie E Bearden, Kristin Cadenhead, Tyrone D Cannon, Ricardo E Carrión, Barbara Cornblatt, Matcheri Keshavan and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Daniel BelloDepartment of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center.
Sophia H BlythDepartment of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center.
Rachel A RabinDepartment of Psychiatry, McGill University, Montreal, Canada and The Douglas Mental Health University Institute, Verdun, Canada.
Jean AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada.
Carrie E BeardenSemel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Behavioral Sciences and Psychology, University of California, Los Angeles, Los Angeles, CA, USA.
Kristin CadenheadDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Tyrone D CannonDepartment of Psychology and Psychiatry, Yale University, New Haven, CT, USA.
Ricardo E CarriónDepartment of Psychiatry, Zucker Hillside Hospital and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, NY, USA.
Barbara CornblattDepartment of Psychiatry, Zucker Hillside Hospital and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Glen Oaks, NY, USA.
Matcheri KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Larry SeidmanDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
William S StoneDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Ming T TsuangDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Elaine F WalkerDepartment of Psychology, Emory University, Atlanta, GA, USA.
Scott WoodsDepartment of Psychiatry, Yale University, New Haven, CT, USA.ORCID 0000-0002-3103-5228
Roscoe O BradyDepartment of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Heather Burrell WardDepartment of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center.ORCID 0000-0003-2901-8004

Funding

STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GREEN, MICHAEL F. · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
Alcohol Research in the Science/Practitioner ModelT32AA013525 · NIAAA · SAN DIEGO STATE UNIVERSITY · PI EDWARD P RILEY, ANDREA SPADONI TOWNSEND · 2002 to 2026
$8.4M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
Network Mediation of Experiential and Expressive Deficits in Psychotic DisordersR01MH116170 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Roscoe O. Brady, KATHRYN Eve LEWANDOWSKI · 2019 to 2026
$5.4M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
6/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081944 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CADENHEAD, KRISTIN S. · 2008 to 2018
$4.9M
Functional Brain Abnormalities in the Schizophrenia ProdromeR01MH076989 · NIMH · YALE UNIVERSITY · PI MATHALON, DANIEL H · 2007 to 2014
$2.3M
Enhancing the Prospective Prediction of PsychosisU01MH066069 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2003 to 2007
$1.5M
Enhancing the Prospective Prediction of PsychosisU01MH066134 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI ADDINGTON, JEAN M · 2003 to 2007
$869k
NIAAA NIH HHS T32 AA013525NIDA NIH HHS K23 DA059690NIMH NIH HHS P50 MH066286NIMH NIH HHS R01 MH076989NIMH NIH HHS R01 MH116170NIMH NIH HHS U01 MH066069NIMH NIH HHS U01 MH066134NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081944NIMH NIH HHS U01 MH081988NIMH NIH HHS U01 MH082022
6 · The paper itself

Abstract

Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco ("co-use") is rising in the general population but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric symptoms and the development of psychosis. We used the North American Prodrome Longitudinal Study 2, a multi-site prospective study of individuals at clinical high risk for psychosis (CHR) and healthy controls, to examine baseline differences in psychiatric symptoms and conversion to psychosis across substance groups: 1) CHR tobacco use, 2) CHR cannabis use, 3) CHR co-use, 4) CHR non-tobacco or cannabis substance use, 5) CHR without substance use, and 6) healthy controls. Among 1,014 participants (734 CHR, 280 controls), more frequent cannabis and tobacco use was linked to greater psychiatric symptom severity, including psychosis, anxiety, and depression. In survival analyses, co-use (HR

Indexed as

cannabisclinical high riskconversion riskco-usepsychosistobacco

Identifiers

PMID41001470
PMCPMC12458528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.